about
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort StudyMethodological issues in papers on IFN therapy: time for reappraisal.Parent training education program: a pilot study, involving families of children with Prader-Willi syndrome.Acute hepatitis B in patients with or without underlying chronic HCV infection.Hepatitis C virus infection and alanine transaminase levels in the general population: a survey in a southern Italian town.Helicobacter pylori seroprevalence in selected groups of Albanian volunteers.Premature ovarian senescence and high miscarriage rate impair fertility in women with hepatitis C virus infection.Modelling cost-effectiveness and health gains of a "universal" vs. "prioritized" HCV treatment policy in a real-life cohort.Woodchuck hepatitis virus core gene deletions and proliferative responses of peripheral blood mononuclear cells stimulated by an immunodominant epitope: a viral immune escape in the woodchuck model of chronic hepatitis B?Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network.Hepatitis E virus and hepatitis A virus exposures in an apparently healthy high-risk population in Italy.Nucleic acid testing (NAT) for HCV RNA in Italian transfusion centres: an external quality assessment.High dosage alpha-interferon for treatment of children and young adults with chronic hepatitis C disease.Identification of low HBV-DNA levels by nucleic acid amplification test (NAT) in blood donors.Genotyping HCV isolates from Italy by type-specific PCR assay in the core region.Hepatitis B, C and Delta virus infections in Albanian patients with chronic liver disease: evaluation of possible changes during the last 10 years.Persistence of HCV-RNA in a blood donor with negative antibody assays.Nosocomial transmission in simultaneous outbreaks of hepatitis C and B virus infections in a hemodialysis center.GB virus C/hepatitis G virus exposure in Italian pediatric and young adult thalassemic patients.A unique HAV strain circulated in patients with acute HAV infection with different risk exposures in Tuscany, Italy.Prevalence of TT virus in healthy children and thalassemic pediatric and young adult patients.Hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt: a retrospective case-control study.The use of lamivudine for patients with acute hepatitis B (a series of cases).Correlation of alcohol consumption with liver histological features in non-cirrhotic patients.Rapid emergence of a viral resistant mutant in WHV chronically infected woodchucks treated with lamivudine and a pre-S/S CHO-derived hepatitis B virus vaccine.Hepatitis B virus infection in health care workers in Albania: a country still highly endemic for HBV infection.Seroprevalence of hepatitis E virus (HEV) antibody and the possible association with chronic liver disease: a case-control study in Albania.The relationships of chronic hepatitis and cirrhosis to alcohol intake, hepatitis B and C, and delta virus infection: a case-control study in Albania.Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study.Effect of an immunogenic complex containing WHV viral particles and non-neutralizing anti-HBs antibodies on the outcome of WHV infection in woodchucks.Mixed cryoglobulinaemia: An important but frequently unrecognized and underestimated HCV-related condition in the real life practice.Corrigendum to "Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV" [J Hepatol 68 (2018) 33-41].Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling studyClinical and virological characteristics of HIV and HCV co-infected versus HCV monoinfected patients: A real-life evaluation in the PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohortHCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort studyPITER: An ongoing nationwide study on the real-life impact of direct acting antiviral based treatment for chronic hepatitis C in ItalyRisk factors among coronary heart disease patients in the context of the Albanian paradoxPrimary hepatocellular cancer in the explanted liver: Outcome of transplantation and risk factors for HCC recurrence[406] RAPID INSURGENCE OF A VIRAL RESISTANT MUTANT IN WHV CHRONICALLY INFECTED WOODCHUCKS TREATED WITH LAMIVUDINE AND A PRE-S/S CHO-DERIVED HEPATITIS B VIRUS VACCINE
P50
Q31168033-B935CABE-CD2A-4938-A2F5-6CBA8A987E40Q33940500-E564BDE5-1779-4B20-834F-BBCA18C1FD06Q38815150-B445DC78-EA4A-407B-BC0B-F601F5A84513Q38909073-139E87EE-60EC-4349-8377-08CAF8371A79Q39542487-D7B7AA26-96F3-483F-B3DB-00018F5F4798Q39850801-03CECAA2-FA53-479C-963D-0EDB29033E79Q40052712-6BC4C488-29D4-4CDA-B037-26125FF76C3EQ40121053-5F622935-347E-4085-BD61-D2B3C5639534Q41493609-A27BBEEC-4AC6-46DA-B73F-04E12A7C73FEQ41924669-69D70984-2794-483E-B6F1-D8F228269CAEQ42281689-F939410E-3BD1-41CB-9D76-2824CBC0078BQ42977039-FB72F492-A9AC-40EC-A65D-B4ADC183490AQ42985683-F4494C75-B205-431A-8C5D-4FBE7AD15BE1Q42989199-DEC0C2F6-5823-4DE2-83B6-50A0B99FAF7CQ42990461-6E06799E-7055-473D-8902-00B464285F18Q42990717-494ACE31-4D18-45DD-95FC-529D5D1A9C11Q42993666-B2D260C5-2DB0-424B-A30C-C1B2EC90D3F2Q43001218-446E2639-0DF4-4A7C-A93F-DE814FF6E2EDQ43034146-A1590B1F-95A4-4BD0-9551-F543E6D3ADC0Q43570635-DD865BD1-590E-4614-9A18-832CF4A1B1F6Q44670694-B8C2858C-73C0-4B12-B858-3C3248980B88Q44693272-2313FFD6-C5F1-4C1D-BBAC-9F2E721055D6Q45051769-BEC791BA-886A-4466-AE1D-557C55CCA1C9Q45240435-78975667-1A28-4161-8A3E-9AE79366457CQ45403552-C925FB3E-C686-4621-A8B8-14382BC11422Q45405645-CE58B43D-4088-4831-A4B9-B9F2D645FBDBQ45420872-716DD26A-3AB0-442D-81D3-9B1BD14EE0C1Q45752690-3D2B6944-A71B-4A01-AAA9-7E6212DB06ABQ47223728-14975E6A-B979-4F7B-A124-F76D94F1F17CQ48061524-DBA62B79-E7E0-40C8-AA56-C7B70A483F2FQ48298626-5B2B3B80-1D24-4F1F-95F0-9FD5D7EE1E72Q49796362-EC601E29-A326-4BBF-98D8-6E5AF9C6461CQ56379401-A84EA913-BFF2-46C0-A159-25C2D4019972Q56830540-7D86AE07-07C4-41A3-8D59-65BEB8856A90Q60331138-0E425E57-80BE-45B8-A4C5-E4E10149C9CEQ60331142-B1C8559E-88C5-48CB-A4F5-AF4D09393CDAQ60331148-99F0223C-DFEE-4064-8EDD-D18AA57344ECQ60331155-92D9643F-AF32-4A81-95B8-2A54BFA03906Q60331160-697714A2-0701-4EA3-9502-9F9BA835FB79Q60331164-6CF0B019-8152-4375-B2B1-6ACA94637525
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Loreta A. Kondili
@ast
Loreta A. Kondili
@en
Loreta A. Kondili
@es
Loreta A. Kondili
@nl
Loreta A. Kondili
@sl
type
label
Loreta A. Kondili
@ast
Loreta A. Kondili
@en
Loreta A. Kondili
@es
Loreta A. Kondili
@nl
Loreta A. Kondili
@sl
prefLabel
Loreta A. Kondili
@ast
Loreta A. Kondili
@en
Loreta A. Kondili
@es
Loreta A. Kondili
@nl
Loreta A. Kondili
@sl
P1053
J-8784-2016
P106
P1153
6603371362
P21
P31
P3829
P496
0000-0003-2656-224X